COMMUNIQUÉS West-GlobeNewswire

Egle Therapeutics Announces Positive Phase 1 Data for EGL-003, Showing Favorable Safety and Selective Treg Expansion in Healthy Volunteer Study
30/09/2026
EGL-003, a selective IL-2 agonist, was well tolerated across all four dose cohorts. EGL-003 produced selective, dose-dependent Treg expansion without amplification of conventional CD4, CD8 or NK cell populations. [...]
Navigator Medicines Presents New Data at EADV 2026 as Bispecific Antibody Program Advances at Speed in Hidradenitis Suppurativa
30/09/2026
Phase 2a MAINSAIL Trial of NAV-240 in Hidradenitis Suppurativa (HS) Recruiting Ahead of Schedule Early Cohorts in Phase 1 Study of Next-Generation Subcutaneous Bispecific Antibody NAV-242 Indicate Extended Half Life ( [...]
Roche’s fenebrutinib is the first BTK inhibitor to receive U.S. FDA filing acceptance in both relapsing and primary progressive multiple sclerosis
30/09/2026
Fenebrutinib cut relapses by 51% and 58% vs teriflunomide in Phase III RMS trials (FENhance 1 & 2) while showing a consistent, positive trend in delaying disability 1 Fenebrutinib became the first investigational [...]
Santhera Pharmaceuticals Half Year Results for the six months ending 30 June 2026
30/09/2026
Ad hoc announcement pursuant to Art. 53 LR. A conference call will be held on September 30, 2026, at 14:00 CEST / 13:00 BST / 08:00 EDT. Details are at the end of this news release Strong momentum and expanding global [...]
Byron Medical Announces the Product Release of ZUMAX Surgical Microscopes: Setting a New Standard of Advanced Precision Dentistry
30/09/2026
BRISBANE, Australia, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Byron Medical is proud to announce the launch of Zumax: a range of advanced surgical microscopes across Australia and New Zealand, giving dentists and specialists [...]
DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years
30/09/2026
Châtillon, France, September 29, 2026 DBV Technologies Announces Submission of Biologics License Ap p lication to U.S. FDA for the VIASKIN ® Peanut Patch in Children Aged 4-7 Years The BLA is supported by the results [...]
DBV Technologies annonce le dépôt de sa demande de licence biologique (BLA) auprès de la Food and Drug Administration des Etats-Unis pour le patch VIASKIN® Peanut destiné aux enfants âgés de 4 à 7 ans.
30/09/2026
Châtillon, France, le 29 septembre 2026 DBV Technologies annonce le dépôt de sa demande de licence biologique (BLA) auprès de la Food and Drug Administration des Etats-Unis pour le patch VIASKIN ® Peanut destiné aux [...]
Zealand Pharma to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD 2026 and announces publication of trial results in The Lancet Diabetes & Endocrinology
30/09/2026
Press release – No. 18 / 2026 Zealand Pharma to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD 2026 and announces publication of trial results in The Lancet Diabetes & Endocrinology [...]
Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson’s Disease and Movement Disorders
29/09/2026
BETHESDA, Md., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of [...]
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
29/09/2026
WAYNE, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated [...]
Acquisition of Own Shares
29/09/2026
Mechelen, Belgium; 29 September 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") [...]
Cuprina Holdings (Cayman) Limited Announces Closing of Underwriter’s Over-Allotment Option in Connection with Public Offering
29/09/2026
SINGAPORE, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited ( Nasdaq: CUPR ) (“ Cuprina ” or “ the Company ”), a biomedical company developing and marketing products for the chronic wounds, [...]
Immunocine Names Janet Maendel, DO (EU), DNM, Director of Clinical Affairs
29/09/2026
Expanded role strengthens clinical interpretation, longitudinal patient assessment, and the scientific framework surrounding Immunocine’s Double-Loaded dendritic cell treatment program HOUSTON, Sept. 29, 2026 (GLOBE [...]
Nox Peptides Introduces Educational Resources and Research Tools for Peptide Science
29/09/2026
TORONTO, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Nox Peptides has introduced a collection of educational resources and practical research tools designed to help readers and researchers better understand peptide science and [...]
HL7 Launches Break the Code to Build the Next Generation of Healthcare Interoperability Talent
29/09/2026
Free global program gives students hands-on experience building FHIR applications and earning HL7 credentials ANN ARBOR, Mich., Sept. 29, 2026 (GLOBE NEWSWIRE) -- With demand for healthcare interoperability expertise [...]
CVRx Announces Late-Breaking Data and New Clinical Evidence on Barostim at the HFSA Annual Scientific Meeting 2026
29/09/2026
MINNEAPOLIS, Sept. 29, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with [...]
Pyxis Oncology Announces Proposed Public Offering
29/09/2026
BOSTON, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that it has commenced a [...]
Vireo Growth Inc. Announces Put/Call Agreement in Connection with Loan Acquisition
29/09/2026
MINNEAPOLIS, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Vireo Growth Inc. (CSE: VREO) (OTCQX: VREOF) (“Vireo” or the “Company”), a leading cannabis company and agricultural markets platform, today announced that it has entered [...]
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
29/09/2026
RADNOR, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in [...]

Pages